In the open-label, non-randomized KEYNOTE basket trial for solid tumors harboring PD-L1, the recurrent GBM cohort enrolled 26 adult patients who received pembrolizumab every 2 weeks for up to 2 years. Here, CD274 is linked to glioblastoma.